First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
"Management stated, 'We are excited about the promising results from our latest trials, which position us well for future growth.'"
Moat: Cogent's proprietary drug discovery platform provides a strong barrier to entry against competitors.
growth - Investors looking for high-risk, high-reward opportunities in biotechnology.
Moderate - Rising interest rates could increase the cost of capital for R&D financing, impacting future growth potential.
Watch on earnings: Clinical trial success rates, Cash runway (months until funding is needed), Partnership deal values.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $12M to $349M as recent phase 2 trial results for cogt-101 showed a 70% response rate in targeted patient populations.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.